3000 Participants Needed

Progression Study for Barrett's Esophagus

AD
TB
CC
Overseen ByCarly Campbell, MS
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Midwest Biomedical Research Foundation
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

The trial aims to identify factors, such as smoking or family history, that increase the risk of esophageal cancer and to study genetic changes that might lead to this cancer. The study focuses on individuals with gastroesophageal reflux disease (GERD) and Barrett's esophagus (BE), conditions that can affect the esophagus. Patients at the Kansas City VA Hospital with confirmed BE or reflux disease are well-suited for this trial. As an unphased trial, it offers participants the chance to contribute to groundbreaking research that could enhance the understanding and prevention of esophageal cancer.

Why are researchers excited about this trial?

Researchers are excited about this trial because it aims to deepen our understanding of the progression of gastroesophageal reflux disease (GERD) and Barrett's esophagus. Unlike treatments that focus solely on symptom relief, this trial is about creating a comprehensive registry that tracks how these conditions develop over time. By gathering detailed data, researchers hope to uncover new insights that could lead to more effective prevention strategies and innovative treatments in the future. This could be a game-changer in managing these conditions and improving patient outcomes.

Who Is on the Research Team?

PS

Prateek Sharma, MD

Principal Investigator

Department of Veterans Affairs Medical Center of Kansas City

Are You a Good Fit for This Trial?

Inclusion Criteria

All patients must be eligible for care that the Kansas City VA Hospital where this study was approved for enrollment.
Kansas City VA Patients with confirmed BE with and without dysplasia and patients with reflux disease (patients/cases); patients with other indicators for endoscopy such as anemia, weight loss, diarrhea, but without GERD and PE (controls).

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Data Collection

Participants fill out questionnaires on GERD severity and food frequency; data on medications, family history, and social history is collected

Ongoing

Endoscopy and Sample Collection

Endoscopy and pathology reports are reviewed; serum and biopsy samples are collected for future analysis

Ongoing

Follow-up

Participants are monitored for progression of GERD and BE to dysplasia and adenocarcinoma

Long-term

What Are the Treatments Tested in This Trial?

Find a Clinic Near You

Who Is Running the Clinical Trial?

Midwest Biomedical Research Foundation

Lead Sponsor

Trials
26
Recruited
9,300+

Kansas City Veteran Affairs Medical Center

Collaborator

Trials
24
Recruited
8,600+